Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 265937 | Other Identifier | Health Canada, Control Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In 2012, it was estimated that nearly 1 in 4 Canadians suffer from allergic rhinitis. To add, 78% of individuals working in predisposing environments are predicted to develop occupational rhinitis. Currently, the most popular treatment for rhinitis is antihistamine medication such as diphenhydramine, a first-generation antihistamine sold commercially as Benadryl®. Due it its anticholinergic effects, diphenhydramine has been suggested to impair the whole body sweating response during heat stress, potentially leaving consumers at an increased risk of heat-related illness. This randomized control trial approved by Health Canada will investigate whether ingesting extra strength diphenhydramine (50mg) will alter whole-body sweat losses during 60 minutes of exercise.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention Order (Placebo - Diphenhydramine) | Other | On separate days, participants will march on a treadmill for 60 minutes at a fixed rate of oxygen consumption (~1.75 liters of oxygen consumption per minute) in ~28°C and 30% relative humidity |
|
| Intervention Order (Diphenhydramine -Placebo) | Other | On separate days, participants will march on a treadmill for 60 minutes at a fixed rate of oxygen consumption (~1.75 liters of oxygen consumption per minute) in ~28°C and 30% relative humidity |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Placebo | Drug | A placebo pill (i.e., sugar) will be consumed 2 h before intervention. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Whole body sweat loss | Change in body mass from pre- to post-exercise corrected for respiratory and metabolic water losses using a digital platform scale accurate to +/- 2 grams. | Measured during both placebo and diphenhydramine intervention trials trials, separated by no more than 28 days |
| Measure | Description | Time Frame |
|---|---|---|
| Change in rectal temperature | Change in rectal temperature from pre- to post- exercise using a pediatric grade thermistor | Measured during both placebo and diphenhydramine intervention trials trials, separated by no more than 28 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nicholas Ravanelli, PhD | Lakehead University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Lakehead Unviersity | Thunder Bay | Ontario | P7B 5E1 | Canada |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39140777 | Derived | Newhouse D, Mihalcin E, Lefebvre K, Nucci M, Ravanelli N. Thermal and Cardiovascular Responses during Exertional Heat Stress after Diphenhydramine Use: A Randomized Crossover Trial. Med Sci Sports Exerc. 2024 Dec 1;56(12):2328-2337. doi: 10.1249/MSS.0000000000003527. Epub 2024 Jul 31. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000084462 | Hyperthermia |
| D065631 | Rhinitis, Allergic |
| ID | Term |
|---|---|
| D001832 | Body Temperature Changes |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D018882 | Heat Stress Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D004155 | Diphenhydramine |
| ID | Term |
|---|---|
| D005021 | Ethylamines |
| D000588 | Amines |
| D009930 | Organic Chemicals |
| D001559 | Benzhydryl Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Double-blind
| Diphenhydramine | Drug | Extra strength Benadryl (DIN 02470144) will be consumed 2 h before intervention |
|
| D014947 | Wounds and Injuries |
| D012220 | Rhinitis |
| D009668 | Nose Diseases |
| D012140 | Respiratory Tract Diseases |
| D012130 | Respiratory Hypersensitivity |
| D010038 | Otorhinolaryngologic Diseases |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
| D001555 |
| Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |